Compare CVS Health Corp (CVS) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs MakeMyTrip Ltd — how do they compare? CVS Health Corp trades at $105.26 (market cap $135.48B), while MakeMyTrip Ltd trades at $56.02 (market cap $5.29B). The key difference: CVS Health Corp is far larger — about 25.6× MakeMyTrip Ltd's market cap, and CVS Health Corp pays a 2.51% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals.
| CVS | MMYT | |
|---|---|---|
Market Cap | $135.48B | $5.29B |
Sector | Health | Technology |
52-Week High | $106.18 | $103.21 |
52-Week Low | $58.75 | $36.30 |
Enterprise Value | $202.02B | $5.93B |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
MakeMyTrip (MMYT) trades at $57.08, down 2.63% today but maintains a bullish technical outlook with strong analyst support. The company demonstrates robust fundamentals with $978M revenue and $95M net income for 2025, though 2026 projections show margin compression. Recent earnings beats and a 73% gross margin highlight operational strength, while technical indicators show bullish moving averages despite recent price weakness.
The stock presents a compelling growth opportunity with strong analyst consensus (73% buy ratings) and consistent earnings outperformance. However, elevated P/E ratio (154.86) and projected margin pressure in 2026 warrant caution. Key risks include travel industry volatility and rising debt-to-asset ratio from 12% to 81% projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
